Revolution Medicines (RVMDW) Operating Expenses (2019 - 2026)
Revolution Medicines (RVMDW) posted quarterly Operating Expenses of $445.2 million for Q1 2026, up 84.92% year-over-year from $240.8 million in Q1 2025, and up 23.12% quarter-over-quarter from $361.6 million in Q4 2025.
Revolution Medicines (RVMDW) Operating Expenses (2019 - 2026) Analysis & Trends
Revolution Medicines' Operating Expenses history runs 8 years deep, the most recent figure standing at $445.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 84.92% year-over-year to $445.2 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 75.68% YoY), while the FY2025 annual figure was $1.2 billion, up 71.48% from the prior year.
- Operating Expenses for Q1 2026 stood at $445.2 million, up from $361.6 million in the prior quarter.
- The five-year high for Operating Expenses was $445.2 million in Q1 2026, with the low at $65.5 million in Q1 2022.
- The 5-year median for Operating Expenses is $156.6 million (2024), against an average of $182.9 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses soared 134.6% in 2023, then increased 19.69% in 2024.
- Revolution Medicines' Operating Expenses stood at $77.0 million in 2022, then jumped by 134.6% to $180.7 million in 2023, then grew by 19.69% to $216.3 million in 2024, then soared by 67.18% to $361.6 million in 2025, then climbed by 23.12% to $445.2 million in 2026.
- Business Quant data shows RVMDW's Operating Expenses at $445.2 million in Q1 2026, $361.6 million in Q4 2025, and $315.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - | 505.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 505.13 Mn |
| Mar 31, 2026 | 445.22 Mn |
| Dec 31, 2025 | 361.63 Mn |
| Sep 30, 2025 | 315.27 Mn |
| Jun 30, 2025 | 264.71 Mn |
| Mar 31, 2025 | 240.76 Mn |
| Dec 31, 2024 | 216.31 Mn |
| Sep 30, 2024 | 175.71 Mn |
| Jun 30, 2024 | 156.64 Mn |
| Mar 31, 2024 | 140.86 Mn |
| Dec 31, 2023 | 180.73 Mn |
| Sep 30, 2023 | 123.25 Mn |
| Jun 30, 2023 | 112.62 Mn |
| Mar 31, 2023 | 82.17 Mn |
| Dec 31, 2022 | 77.04 Mn |
| Sep 30, 2022 | 79.89 Mn |
| Jun 30, 2022 | 71.21 Mn |
| Mar 31, 2022 | 65.53 Mn |
| Dec 31, 2021 | 62.37 Mn |
| Sep 30, 2021 | 54.26 Mn |